TPTE and melanoma: Lipo-MERIT trial (NCT02410733), a phase I study investigating the use of personalized mRNA vaccines (BNT111) targeting four specific neoantigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) in melanoma patients, aiming to stimulate a potent immune response by training T cells to recognize and destroy tumor cells expressing these mutations, with promising results observed when combined with checkpoint inhibitors [133].